Maravai LifeSciences Holdings, Inc. — Form 8-K Summary
Reporting date: July 19, 2023, with the director appointment effective July 20, 2023. The filing reports corporate governance changes and related Regulation FD disclosure; it does not provide financial results for a reporting period.
Business Context and Reporting Period
Maravai LifeSciences Holdings, Inc. is a Delaware corporation headquartered in San Diego, California. Its Class A common stock trades on Nasdaq under the symbol MRVI.
Financial Metrics and Capital Structure
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
- No changes to the company’s capital structure, credit facilities, or financial condition are disclosed.
Material Changes and Governance Developments
- Robert B. Hance resigned from the Board effective July 19, 2023.
- The filing states that Mr. Hance’s resignation was not related to any disagreement with management, the Board, or any Board committee regarding company operations, policies, or practices.
- On July 20, 2023, the Board appointed John DeFord, Ph.D. to fill the vacancy.
- Dr. DeFord will serve as a Class II director until the 2025 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier resignation or removal.
- Dr. DeFord had not been appointed to any Board committee as of the filing.
Compensation, Disclosures, and Risks
- Dr. DeFord will receive compensation under the company’s previously disclosed non-employee director compensation policy and will enter into the company’s standard indemnification agreement.
- The company reported no arrangement or understanding related to Dr. DeFord’s appointment, no family relationship with company directors or executive officers, and no known related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
- Exhibit 99.1 is a press release dated July 20, 2023 announcing the appointment. The Regulation FD disclosure and exhibit are not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
- No guidance, outlook, contingencies, unusual financial items, or material operating risks are disclosed in the provided filing text.
Key Facts for Investors to Verify
- Confirm the effective dates: Mr. Hance’s resignation was effective July 19, 2023, and Dr. DeFord’s appointment was effective July 20, 2023.
- Review Dr. DeFord’s qualifications and the accompanying Exhibit 99.1 press release.
- Assess whether the Board’s committee composition or governance policies changed after the appointment.
- Refer to the company’s periodic financial filings for revenue, profitability, cash flow, debt, liquidity, and outlook information, which are not included in this 8-K.